Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer


Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.

Related Videos
Related Content